A new CRISPR approach can control genes without cutting DNA, opening a safer path for treating genetic diseases. A newly ...

Precision BioSciences offers high-risk, high-reward potential, trading below cash with key HBV and DMD data catalysts ...

Explore the potential of gene therapy as a groundbreaking approach to curing diseases, beyond traditional pharmacological ...

As of Tuesday, December 23, Tenaya Therapeutics, Inc.’s TNYA share price has dipped by 9.52%, which has investors questioning if this is right time to buy.

As of Tuesday, December 23, Benitec Biopharma Inc.’s BNTC share price has surged by 5.75%, which has investors questioning if this is right time to sell.

Phio Pharmaceuticals ( ($PHIO) ) has provided an announcement. On December 23, 2025, Phio Pharmaceuticals announced that the U.S. Food and Drug ...

Nonclinical protocol study design accepted by FDA Study to commence in First Quarter 2026King of Prussia, Pennsylvania--(Newsfile Corp. - December 23, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) ...

Nonclinical protocol study design accepted by FDA Study to commence in First Quarter 2026King of Prussia, ...

Incentive scheme for rare disease drug development vital for sector, says leading biotechSynaptixBio, the only company licensed to commercialise a treatment for a rare, deadly disease, says the ...

Arrowhead Pharmaceuticals, Inc. today announced that it is scheduled to participate in the following upcoming events: Obesity KOL Webinar ? ARO-INHBE and ARO-ALK7 Interim Clinical Data ? January 6, ...

Against this backdrop, a research team led by Dr. Guozhang Kang and Dr. Gezi Li from Henan Agricultural University, China, ...

That’s because the industry veteran will join Alnylam’s board as of Jan. 5. Arbuckle had been executive vice president and ...